TYENNE DIN 02552469
Status: Marketed
Holder: FRESENIUS KABI CANADA LTD
Health Canada record
| Active ingredient(s) | TOCILIZUMAB 200 MG |
|---|
| Dosage form | Solution |
|---|
| Route | Intravenous |
|---|
| Schedule | SCHEDULE D; PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | L04AC07 TOCILIZUMAB |
|---|
| Original market date | 14-Apr-2025 |
|---|
| Current status date | 14-Apr-2025 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Fresenius Kabi Canada Ltd. — licence 102232, currently licensed, last inspection rating C (2025-10-01).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing TOCILIZUMAB
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02350092 | ACTEMRA | HOFFMANN-LA ROCHE LIMITED | Solution | TOCILIZUMAB 80 MG | Marketed |
| 02350106 | ACTEMRA | HOFFMANN-LA ROCHE LIMITED | Solution | TOCILIZUMAB 200 MG | Marketed |
| 02350114 | ACTEMRA | HOFFMANN-LA ROCHE LIMITED | Solution | TOCILIZUMAB 400 MG | Marketed |
| 02424770 | ACTEMRA | HOFFMANN-LA ROCHE LIMITED | Solution | TOCILIZUMAB 162 MG | Marketed |
| 02483327 | ACTEMRA | HOFFMANN-LA ROCHE LIMITED | Solution | TOCILIZUMAB 162 MG | Marketed |
| 02562049 | AVTOZMA | CELLTRION INC. | Solution | TOCILIZUMAB 400 MG | Marketed |
| 02562022 | AVTOZMA | CELLTRION INC. | Solution | TOCILIZUMAB 80 MG | Marketed |
| 02562030 | AVTOZMA | CELLTRION INC. | Solution | TOCILIZUMAB 200 MG | Marketed |
| 02562057 | AVTOZMA | CELLTRION INC. | Solution | TOCILIZUMAB 162 MG | Marketed |
| 02562065 | AVTOZMA | CELLTRION INC. | Solution | TOCILIZUMAB 162 MG | Marketed |
| 02552477 | TYENNE | FRESENIUS KABI CANADA LTD | Solution | TOCILIZUMAB 400 MG | Marketed |
| 02552485 | TYENNE | FRESENIUS KABI CANADA LTD | Solution | TOCILIZUMAB 162 MG | Marketed |
| 02552493 | TYENNE | FRESENIUS KABI CANADA LTD | Solution | TOCILIZUMAB 162 MG | Marketed |
| 02552450 | TYENNE | FRESENIUS KABI CANADA LTD | Solution | TOCILIZUMAB 80 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 34185 | 2024-10-11 | New Drug Submission (NDS) | |
Request a quote for TYENNE
How to read a Canadian DIN record